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N Purpose.—To develop a guideline to improve the
accuracy of immunohistochemical (IHC) estrogen receptor
(ER) and progesterone receptor (PgR) testing in breast
cancer and the utility of these receptors as predictive
markers.
Methods.—The American Society of Clinical Oncology
and the College of American Pathologists convened an
international Expert Panel that conducted a systematic
review and evaluation of the literature in partnership with
Cancer Care Ontario and developed recommendations for
optimal IHC ER/PgR testing performance.
Results.—Up to 20% of current IHC determinations of
ER and PgR testing worldwide may be inaccurate (false
negative or false positive). Most of the issues with testing
have occurred because of variation in preanalytic
variables, thresholds for positivity, and interpretation
criteria.
Recommendations.—The Panel recommends that ER and
PgR status be determined on all invasive breast cancers and
breast cancer recurrences. A testing algorithm that relies
on accurate, reproducible assay performance is proposed.
Elements to reliably reduce assay variation are specified. It
is recommended that ER and PgR assays be considered
positive if there are at least 1% positive tumor nuclei in the
sample on testing in the presence of expected reactivity of
internal (normal epithelial elements) and external controls.
The absence of benefit from endocrine therapy for women
with ER-negative invasive breast cancers has been con-
firmed in large overviews of randomized clinical trials.
(Arch Pathol Lab Med. 2010;134:907–922)
INTRODUCTION
In 2008, the American Society of Clinical Oncology
(ASCO) and the College of American Pathologists (CAP)
decided to pursue an investigation of whether a
guideline for estrogen receptor (ER) and progesterone
receptor (PgR) testing would be necessary and beneficial
for patients with breast cancer. The two organizations
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had published a joint guideline on human epidermal
growth factor receptor 2 (HER2) testing in 2007.1,2 A new
Expert Panel was convened to address this issue in 2008,
and a document reflecting their expert and evidence-
based opinions was developed and approved by both
organizations. This version of that document is abbre-
viated from the original approved document, which is
available online and includes introductory sections
dealing with ER physiology and measurement, history
of ER testing, and discussion of the current issues
Table 1. Summary of Guideline Recommendations for ER and PgR Testing by IHC in Breast Cancer Patients
Recommendation Comments
Optimal algorithm for
ER/PgR testing
Positive for ER or PgR if finding of $ 1% of
tumor cell nuclei are immunoreactive
These definitions depend on laboratory documentation of
the following:
Negative for ER or PgR if finding of , 1% of
tumor cell nuclei are immunoreactive in the
presence of evidence that the sample can
express ER or PgR (positive intrinsic controls
are seen)
1. Proof of initial validation in which positive ER or PgR
categories are 90% concordant and negative ER or
PgR categories are 95% concordant with a clinically
validated ER or PgR assay.3
Uninterpretable for ER or PgR if finding that
no tumor nuclei are immunoreactive and that
internal epithelial elements present in the
sample or separately submitted from the same
sample lack any nuclear staining
2. Ongoing internal QA procedures, including use of
external controls of variable ER and PgR activity with
each run of assay, regular assay reassessment, and
competency assessment of technicians and
pathologists.
3. Participation in external proficiency testing according
to the proficiency testing program guidelines.
4. Biennial accreditation by valid accrediting agency.
Optimal testing
conditions
Large, preferably multiple core biopsies of tumor
are preferred for testing if they are representative
of the tumor (grade and type) at resection.
Specimen should be rejected and testing repeated on a
separate sample if any of the following conditions exist:
1. External controls are not as expected (scores recorded
daily show variation).
2. Artifacts involve most of sample.
Specimen may also be rejected and testing repeated on
another sample if:
1. Slide has no staining of included normal epithelial
elements and/or normal positive control on same
slide.
2. Specimen has been decalcified using strong acids.
3. Specimen shows an ER-negative/PgR-positive
phenotype (to rule out a false-negative ER assay or a
false-positive PgR assay).
4. Sample has prolonged cold ischemia time or fixation
duration , 6 hours or . 72 hours and is negative on
testing in the absence of internal control elements.
Interpretation follows guideline recommendation. Positive ER or PgR requires that $ 1% of tumor cells are
immunoreactive. Both average intensity and extent of
staining are reported.
Image analysis is a desirable method of quantifying
percentage of tumor cells that are immunoreactive.
H score, Allred score, or Quick score may be provided.
Negative ER or PgR requires , 1% of tumor cells with ER
or PgR staining.
Interpreters have method to maintain consistency and
competency documented regularly.
Accession slip and report must include
guideline-detailed elements.
Optimal tissue
handling
requirements
Time from tissue acquisition to fixation should
be as short as possible. Samples for ER and
PgR testing are fixed in 10% NBF for 6 to 72
hours. Samples should be sliced at 5-mm
intervals after appropriate gross inspection and
margins designation and placed in sufficient
volume of NBF to allow adequate tissue
penetration. If tumor comes from remote
location, it should be bisected through the
tumor on removal and sent to the laboratory
immersed in a sufficient volume of NBF. Cold
ischemia time, fixative type, and time the
sample was placed in NBF must be recorded.
As in the ASCO/CAP HER2 guideline, storage
of slides for more than 6 weeks before analysis
is not recommended.
Time tissue is removed from patient, time tissue
is placed in fixative, duration of fixation, and
fixative type must be recorded and noted on
accession slip or in report.
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related to ER and PgR testing for patients with breast
cancer.
GUIDELINE QUESTIONS
The overall purpose of this guideline is to improve the
accuracy of hormone receptor testing and the utility of ER
and PgR as prognostic and predictive markers for
assessing in situ and invasive breast carcinomas. There-
fore, this guideline addresses two principal questions
regarding ER and PgR testing. Findings are listed in
Table 1.
1. What is the optimal testing algorithm for determin-
ing ER and PgR status?
1.1. What are the clinically validated methods that
can be used in this assessment?
2. What strategies can ensure optimal performance,
interpretation, and reporting of established assays?
2.1. What are the preanalytic, analytic, and post-
analytic variables that must be controlled to
ensure that assay results reflect tumor ER and
PgR status?
2.2. What is the optimal internal quality manage-
ment regimen to ensure ongoing accuracy of
ER and PgR testing?
2.3. What is the regulatory framework that permits
application of external controls such as profi-
ciency testing and on-site inspection?
2.4. How can internal and external control efforts be
implemented and their effects measured?
The Panel also reviewed a few special questions.
1. Should immunohistochemistry (IHC) of ER/PgR be
performed in ductal carcinoma in situ (DCIS) or recurrent
breast cancer specimens?
2. Does PgR expression in breast cancer correlate with
or influence the choice of endocrine therapy?
PRACTICE GUIDELINES
ASCO/CAP’s practice guidelines reflect expert consen-
sus based on the best available evidence. They are
intended to assist physicians and patients in clinical
decision making and to identify questions and settings for
further research. With the rapid flow of scientific
information in oncology, new evidence may emerge
between the time an updated guideline was submitted
for publication and when it is read or appears in print.
Guidelines are not continually updated and may not
reflect the most recent evidence. Guidelines address only
the topics specifically identified in the guideline and are
Recommendation Comments
Optimal internal
validation
procedure
Validation of any test must be done before test
is offered. See separate article on testing
validation (Fitzgibbons et al3).
Validation must be done using a clinically
validated ER or PgR test method.
Revalidation should be done whenever there
is a significant change to the test system, such
as a change in the primary antibody clone or
introduction of new antigen retrieval or
detection systems.
Optimal internal QA
procedures
Initial test validation. See separate article on testing
validation (Fitzgibbons et al3).
Ongoing quality control and equipment
maintenance.
Initial and ongoing laboratory personnel training and
competency assessment.
Use of standardized operating procedures including
routine use of external control materials with each
batch of testing and routine evaluation of internal
normal epithelial elements or the inclusion of
normal breast sections on each tested slide,
wherever possible.
Regular, ongoing assay reassessment should be done
at least semiannually (as described in Fitzgibbons
et al3). Revalidation is needed whenever there is a
significant change to the test system.
Ongoing competency assessment and education of
pathologists.
Optimal external
proficiency assessment
Mandatory participation in external proficiency
testing program with at least two testing events
(mailings) per year.
Satisfactory performance requires at least 90%
correct responses on graded challenges for either
test.
Unsatisfactory performance will require laboratory to
respond according to accreditation agency program
requirements.
Optimal laboratory
accreditation
On-site inspection every other year with annual
requirement for self-inspection.
Reviews laboratory validation, procedures, QA results and
processes, and reports.
Unsuccessful performance results in suspension of
laboratory testing for ER or PgR.
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; IHC, immunohistochemistry; QA, quality assurance; NBF, neutral buffered
formalin; ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; HER2, human epidermal growth factor receptor 2.
Continued
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not applicable to interventions, diseases, or stages of
diseases not specifically identified. Furthermore, guide-
lines cannot account for individual variation among
patients and cannot be considered inclusive of all proper
methods of care or exclusive of other treatments. It is the
responsibility of the treating physician or other health care
provider, relying on independent experience and knowl-
edge of the patient, to determine the best course of
treatment for the patient. Accordingly, adherence to any
guideline is voluntary, with the ultimate determination
regarding its application to be made by the physician in
light of each patient’s individual circumstances and
preferences. ASCO/CAP guidelines describe the use of
procedures and therapies in clinical practice and cannot be
assumed to apply to the use of interventions in the context
of clinical trials. ASCO and CAP assume no responsibility
for any injury or damage to persons or property arising
out of or related to any use of ASCO/CAP’s guidelines or
for any errors or omissions.
METHODS
Panel Composition
The ASCO Clinical Practice Guidelines Committee
(CPGC) and the CAP Council on Scientific Affairs (CSA)
jointly convened an Expert Panel (hereafter referred to as
the Panel) consisting of experts in clinical medicine and
research relevant to hormone receptor testing, including
medical oncology, pathology, epidemiology, statistics,
and health services research. Academic and community
practitioners, a patient representative, and experts from
the US National Cancer Institute (NCI) and international
organizations were also part of the Panel. Representatives
from the US Food and Drug Administration (FDA) and
the US Centers for Medicare and Medicaid Services served
as ex-officio members. The opinions of Panel members
associated with official government agencies like the US
National Cancer Institute represent their individual views
and not necessarily those of the agency with which they
are affiliated. The Panel members are listed in Appendix
Table A1 (online only). Representatives of commercial
laboratories and assay manufacturers (Appendix Ta-
ble A2, online only) were invited as guests to attend the
open portion of the 2-day meeting held at ASCO
headquarters in Alexandria, VA, in December 2008. The
planning, deliberations, and manuscript drafting were led
by a six-member steering committee composed of two
ASCO representatives (Drs Hayes and Wolff), two CAP
representatives (Drs Hammond and Schwartz), and two
additional experts in testing and evaluation of ER (Drs
Allred and Dowsett).
Literature Review and Analysis
ASCO/Cancer Care Ontario (CCO) Systematic Review.—
ASCO and CAP commissioned a systematic review of the
literature on hormone receptor testing published since
1990. That review conducted by ASCO and CCO is being
published separately (manuscript in preparation) and
served as the primary source of the evidence for this
guideline. Articles were selected for inclusion in the
systematic review if they met the following prospective
criteria. Studies comparing IHC in paraffin-embedded
female breast cancer sections with another assay and
comparative studies whose objectives were to improve or
validate the quality of IHC studies that linked test
performance to clinical outcome were specifically sought.
Systematic reviews, consensus statements, and practice
guidelines from 1990 onward were included if they
addressed hormone receptor testing in female breast
cancer using IHC in paraffin-embedded sections or gene
expression signatures for ER and PgR. A cutoff date of
1990 was chosen because this was the time that IHC began
to come into common use. Additional details of the
literature search strategy are provided in the Systematic
Review (manuscript in preparation).
ASCO/CAP Expert Panel literature review and analysis.—
The Panel reviewed all data from the systematic review, as
well as additional studies obtained from personal files.
Consensus Development Based on Evidence
The entire Panel met in December 2008, and additional
work on the guideline was completed through e-mail and
teleconferences of the Panel. The purpose of the Panel
meeting was to refine the questions addressed by the
guideline, draft guideline recommendations, and distrib-
ute writing assignments. All members of the Panel
participated in the preparation of the draft guideline
document, which was then disseminated for review by the
entire Panel. The guideline was submitted to Journal of
Clinical Oncology and Archives of Pathology & Laboratory
Medicine for peer review. Feedback from external review-
ers was also solicited. The content of the guidelines and
the manuscript were reviewed and approved by the
ASCO CPGC and Board of Directors and by the CAP CSA
and Board of Governors before publication.
Guideline and Conflict of Interest
The Expert Panel was assembled in accordance with
ASCO’s Conflict of Interest Management Procedures for
Clinical Practice Guidelines (‘‘Procedures,’’ summarized
at www.asco.org/guidelinescoi). Members of the Panel
completed ASCO’s disclosure form, which requires
disclosure of financial and other interests that are relevant
to the subject matter of the guideline, including relation-
ships with commercial entities that are reasonably likely to
experience direct regulatory or commercial impact as the
result of promulgation of the guideline. Categories for
disclosure include employment relationships, consulting
arrangements, stock ownership, honoraria, research fund-
ing, and expert testimony. In accordance with the
Procedures, the majority of the members of the Panel
did not disclose any of these types of relationships.
Disclosure information for each member of the Panel is
published adjunct to this guideline.
Revision Dates
At biannual intervals, the Panel Co-Chairs and two
Panel members designated by the Co-Chairs will deter-
mine the need for revisions to the guidelines based on an
examination of current literature. If necessary, the entire
Panel will be reconvened to discuss potential changes.
When appropriate, the Panel will recommend revised
guidelines to the ASCO CPGC, the CAP CSA, the ASCO
Board, and the CAP Board for review and approval.
Definition of Terms
See Appendix (online only) for definitions of terms used
throughout this document.
910 Arch Pathol Lab Med—Vol 134, June 2010 Breast Cancer Hormone Receptor Guideline, IHC—Hammond et al
Summary of Outcomes Assessed
The primary outcome of interest was the correlation
between hormone receptor status, as tested by various
assays and methods, and benefit from endocrine therapy,
as measured by prolongation of disease-free, progression-
free, or overall survival or, in selected instances, response
rates. Other outcomes of interest included the positive and
negative predictive values, accuracy, and correlation of
assays used to determine hormone receptor status,
including (but not necessarily limited to) specific assay
performance, technique, standardization attempted, qual-
ity assurance, proficiency testing, and individual or
institutional training. Finally, improvement in assay
results based on any of these interventions was examined.
Literature Search
The ASCO/CCO systematic review identified 337
studies that met the inclusion criteria.
RECOMMENDATIONS
What Is the Optimal Testing Algorithm for the Assessment
of ER and PgR Status?
Summary and recommendations.—The Panel reviewed
the literature on ER and PgR testing and discussed its
implications for patients diagnosed with breast cancer.
The purpose of both tests is to help determine likelihood
of patients responding to endocrine therapy. Therefore,
the optimal threshold to define clinical benefit should be
based on thresholds that are clinically validated against
patient outcome in patients treated with endocrine
therapy compared with those who were not.
What Are the Clinically Validated Methods That Can Be
Used in This Assessment?
Table 2 shows significant correlations between ER levels
determined by IHC and clinical outcome in patients with
less advanced disease treated with adjuvant hormonal
therapy. Table 3 lists the assays that are currently
considered to be clinically validated. A thorough discus-
sion of these topics appears in the unabridged version of
this guideline.
Laboratory concordance with standards.—In the case of
IHC assays of ER and PgR assays, there is no gold standard
assay available. The Panel agreed that a relevant standard
would be any assay whose specific preanalytic and analytic
components conformed exactly to assays whose results had
been validated against clinical benefit from endocrine
therapy (clinical validation). Currently, there are several
assay formats that meet this criterion as models against
which a laboratory can compare its testing. Examples
include the ER and PgR methods described in the
publications by Harvey et al6 and Mohsin et al10 and the
FDA 510(k)-cleared ER/PR pharmDx assay kit (Dako,
Glostrup, Denmark). ER can also be determined by
evaluation of RNA message, either by individual assay or
as part of a multigene expression assay, such as a
multigene array or as a multigene quantitative polymerase
chain reaction. For example, the 21-gene recurrence score
(RS) assay includes ER and PgR as one of the genes in the
signature.11 However, comparison between measures of
ER/PgR protein by local IHC and of mRNA by central
reverse transcription polymerase chain reaction showed a
discordance rate of 9% and 12%, respectively,12 and there
are no published correlations of the individual measures of
ER and PgR mRNA from the 21-gene signature with
clinical outcome. As a result of this lack of published data
correlating the ER and PgR individual measures within the
21-gene RS directly with clinical outcome, the Panel
concluded it was premature to recommend these individ-
ual measures for assay standardization and validation.
As discussed later, a laboratory performing ER testing
should initially validate its proposed or existing assay
against one of these clinically validated assays and
demonstrate acceptable concordance. Details of accept-
able validation methods are described in a separate
publication.3 To be considered acceptable, the results of
the assay must be initially 90% concordant with those of
the clinically validated assay for the ER- and PgR-positive
category and 95% concordant for the ER- or PgR-negative
category. Table 3 lists details of clinically validated assays
including reagents, thresholds, and publications.
Definition of positive and negative ER and PgR tests.—The
Panel deliberated carefully about recommending a univer-
sal cut point to distinguish ‘‘positive’’ and ‘‘negative’’ ER
levels by IHC. The original cut point established for the
ligand-binding assays (LBAs) in the 1970s was based
primarily on the odds of response in the metastatic setting
to a variety of endocrine treatments being used at the time
in many centers.18 Cytosol protein 10 fmol/mg was
generally accepted as the optimum clinically useful cut
point, and the FDA-approved kits using radiolabeled LBAs
specified this value. Even then, the odds of responding for
patients with ER levels less than 10 fmol/mg tissue were
greater than 0, and others suggested that lower levels, such
as more than 3 fmol/mg, might be appropriate.19,20
When IHC assays replaced LBAs in the early to mid-
1990s, relatively few clinical studies were performed to
establish optimum cut points for these assays. Instead,
most studies simply compared the two and assumed that
the IHC level corresponding to the previously determined
LBA cut point was also valid. However, some early
studies demonstrated that IHC was equivalent or superior
to LBA in predicting benefit from adjuvant endocrine
therapy.6,10 Others showed significant correlations be-
tween ER levels determined by IHC and clinical outcome
in patients with less advanced disease treated with
adjuvant hormonal therapy (Tables 2 and 3).
Overall, the most comprehensive breast cancer studies
have consistently shown that IHC is equivalent or
superior to LBA in predicting response to hormonal
therapy and that levels as low as 1% positive-staining
carcinoma cells are associated with significant clinical
response (Tables 2 and 3). Therefore, given the substantial
impact of tamoxifen and other endocrine therapies on
mortality reduction and their relatively low toxicity
profile, the Panel recommended that the cutoff to
distinguish ‘‘positive’’ from ‘‘negative’’ cases should be
$ 1% ER-positive tumor cells. The Panel recommended
considering endocrine therapy in patients whose breast
tumors show at least 1% ER-positive cells and withhold-
ing endocrine therapy if less than 1%. We recognize that
these recommendations will result in a slight increase in
the application of endocrine therapy in some practices. We
also recognize that it is reasonable for oncologists to
discuss the pros and cons of endocrine therapy with
patients whose tumors contain low levels of ER by IHC
(1% to 10% weakly positive cells) and to make an informed
decision based on the balance.
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Table 2. ER Expression by Original LBA and Retrospective IHC Versus Benefit From Endocrine Therapy (Selected Trials)
Reference
No. of Patients
(eligibility)
Intervention
(outcome)
Original
Assay
(cutoff)
Retro-
spective
Assay
(cutoff)
Assay
Concordance
Outcome
According to
Biomarker Comments
McCarty
et al4
Pop A, n 5 62
(early stage);
Pop B, n 5 72
(early stage);
Pop C, n 5 23
(MBC)
Endocrine Rx
(Pop C)
LBA ($
20 fmol/mg)
H222 Sp g
Pop (score
75)
Pop A 5
specificity,
89% and
sensitivity,
95%; Pop B
5 specificity,
94% and
sensitivity,
88%
Objective clinical
response:
specificity,
89%;
sensitivity,
93%
Among the
original reports
describing IHC
correlation with
LBA and with
response to
endocrine Rx
Barnes
et al5
170 patients;
74% ER
positive by
LBA
First-line TAM
in MBC (51%
response rate)
LBA; 74% ER
positive ($
20 fmol/
mg);
response
rate, 58%
IHC with
ER 1D5
antibody;
31% to
69% ER
positive
(various
IHC
scoring
methods);
response
rate, 64%
to 69%
137 (81%)
of 170
Responses in
72% of
ER/PgR positive
and 61% of ER
positive/PgR
negative; IHC
superior for
predicting
duration of
response
All 8 IHC scoring
methods useful
Harvey
et al6
1,982 patients 26% received
endocrine Rx
and 13%
received
combined
chemoendocrine
Rx
LBA (positive
if $ 3 fmol/
mg)
IHC with
6F11
(Allred
score . 2
or 1% to
10%
weakly
positive
cells)
71% of all
tumors were
ER positive
by IHC (86%
concordance
with LBA)
Multivariate
analysis of
patients tested
by LBA showed
ER status
determined by
IHC better than
by LBA at
predicting
better DFS
This study was
based on
samples
prepared in an
unconventional
manner (see text
for details)
Elledge
et al7
205 patients
with blocks
(original n 5
349, all ER
positive by
LBA)
SWOG 8228, TAM
10 mg twice a
day (n 5 56) or
10 mg/m2 twice
a day (n 5 149)
LBA (positive
if $ 3 fmol/
mg)
IHC with ER-
6F11
antibody
(Allred
score)
185 (90%) of
205 were
IHC positive
Overall response
rate of 56% if
LBA positive
and 60% if IHC
positive;
significant
correlation
between IHC
ER and
response (ER
negative, 25%;
intermediate,
46%; and high,
66%) and time
to Rx failure (ER
negative,
5 months;
intermediate,
4 months; and
high, 10
months)
In low ER by LBA
(, 50 fmol/mg),
response rate of
25% if IHC
negative and
63% if IHC high
Thomson
et al8
332 patients
(premeno-
pausal
patients with
stage II
disease); 81%
had tumor
assayed for
ER by LBA
Adjuvant OA v
CMF
chemotherapy
LBA originally
done in 270
patients or
81%
(negative if
, 20 fmol/
mg with 2
categories,
or negative
if 0–4 fmol/
mg with 4
categories)
IHC done in
236
patients
(or 71%;
quick
score)
Spearman’s
rank
correlation
coefficient,
0.55
Significant
interaction
between IHC
quick score and
Rx with OA
more beneficial
for patients
with positive
quick score,
whereas
patients with
quick score of 0
had
significantly
higher risk of
death with OA
Original trial 5
better outcome
with OA if ER
. 20 fmol/mg v
with CMF if ER
, 20 fmol/mg
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The percentage of stained tumor cells may provide
valuable predictive and prognostic information to inform
treatment strategies. Eight studies described the relation-
ship between hormone receptor levels and patient
outcomes.5,7,17,21–25 Overall survival,7,23,24 disease-free sur-
vival,24 recurrence/relapse-free survival,22,23 5-year sur-
vival,21 time to treatment failure,7 response to endocrine
therapy,7,25 and time to recurrence17 were all positively
associated with ER levels. Overall survival,7 time to
treatment failure/progression,5,7 response to endocrine
therapy,7,25 and time to recurrence17 were positively
related to PgR levels. These studies suggest that patients
with higher hormone receptor levels will have a higher
probability of positive outcomes and may influence
oncologists’ and patients’ treatment decisions.
Although some studies suggest that the predictive role
of PgR may not be as important clinically as ER,5,13,26 other
studies have shown that PgR status provides additional
predictive value10 independent of ER values,25,27 especially
among premenopausal women.9,22 Again, predictive valid-
ity for PgR has been demonstrated with as few as 1% of
stained tumor nuclei cells in retrospective studies.10,25
Among patients who received adjuvant endocrine therapy,
the best cutoff for both disease-free (adjusted P 5 .0021)
and overall (adjusted P 5 .0014) survival was a total PgR
Allred score of greater than 2, which corresponds to greater
than 1% of carcinoma cells exhibiting weakly positive
staining.10 For patients with metastatic breast cancer who
received first-line endocrine therapy on relapse, a correla-
tion was found between PgR receptor status and response
to endocrine therapy at a 1% staining threshold (P 5 .044)
or response to tamoxifen therapy at 10% (P5 .021) and 1%
staining thresholds (P 5 .047). Furthermore, patients with
carcinomas exhibiting$ 1% PgR staining levels had better
survival after relapse (P 5 .0008).25
Reporting Results
Taking these issues into consideration, the Panel
recommends that ER and PgR results be reported with
three required result elements and two optional result
elements (Table 1). The three required elements are as
follows.
1. The percentage/proportion of tumor cells staining
positively should be recorded and reported; all tumor
containing areas of the tissue section on the slide should
be evaluated to arrive at this percentage. The percentage
can be arrived at either by estimation or by quantification,
either manually by counting cells or by image analysis.
Image analysis holds promise for improving inter- and
intraobserver reproducibility, but controversy exists
about how imaging should be implemented at this time.
Standards of system performance have not yet been
developed. If the sample is a cytology specimen, at least
100 cells should be counted or used to estimate the
percentage of hormone receptor–positive tumor cells,
particularly if the tumor specimen is limited and if the
Continued
Reference
No. of Patients
(eligibility)
Intervention
(outcome)
Original
Assay
(cutoff)
Retro-
spective
Assay
(cutoff)
Assay
Concordance
Outcome
According to
Biomarker Comments
Regan
et al9
571 patients
[premenopausal
(IBCSG trial VIII)]
and 976 patients
[postmenopausal
with node-negative
disease (IBCSG
trials VIII and IX)]
IBCSG trial VIII
(none, CMF,
goserelin, or CMF
R goserelin);
IBCSG trial IX
(TAM or CMF R
TAM)
55% patients
had LBA
(positive if
$ 20 fmol/
mg) and
45% had
ELISA
IHC with
1D5
antibody
(present if
. 0%
stained
cells and
positive if
$ 10%
stained
cells)
Concordance
of 88%
(k 5 0.66) in
postmeno-
pausal
patients
HR similar for
association
between DFS
and ER status
(all patients) or
PgR status
(postmeno-
pausal patients)
as determined
by the various
methods
Abbreviations: ER, estrogen receptor; LBA, ligand-binding assay; IHC, immunohistochemistry; Pop, population; MBC, metastatic breast cancer; Rx,
therapy; TAM, tamoxifen; PgR, progesterone receptor; DFS, disease-free survival; SWOG, Southwest Oncology Group; CMF, cyclophosphamide,
methotrexate, and fluorouracil; OA, ovarian ablation; IBCSG, International Breast Cancer Study Group; ELISA, enzyme-linked immunosorbent assay.
Table 3. Well-Validated Assays for Evaluating Estrogen Receptor and Progesterone Receptor in Breast Cancer
by Immunohistochemistry
Reference Primary Antibody Cut Point for ‘‘Positive’’
Estrogen receptor
Harvey et al, 19996 6F11 Allred score $ 3 (1% to 10% weakly positive cells)
Regan et al, 20069; Viale et al, 200713; Viale
et al, 200814
1D5 1% to 9% (low) and $ 10% (high)
Cheang et al, 200615 SP1 $ 1%
Phillips et al, 200716 ER.2.123 + 1D5 (cocktail) Allred score $ 3 (1% to 10% weakly positive cells)
Dowsett et al, 200817 6F11 H score . 1 ($ 1%)
Progesterone receptor
Mohsin et al, 200410 1294 Allred score $ 3 (1% to 10% weakly positive cells)
Regan et al, 20069; Viale et al, 200713; Viale
et al, 200814
1A6 1% to 9% (low) and $ 10% (high)
Phillips et al, 200716 1294 Allred score $ 3 (1% to 10% weakly positive cells)
Dowsett et al, 200817 312 $ 10%
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positive staining seems to involve only a minority of
tumor cells.
2. The intensity of staining should be recorded and
reported as weak, moderate, or strong; this measurement
should represent an estimate of the average staining of
the intensity of the positively stained tumor cells on the
entire tissue section relative to the intensity of positive
controls run with the same batch. Intensity is provided as
a measure of assay quality over time and also allows for
optional composite scoring.
3. An interpretation of the assay should be provided,
using one of three mutually exclusive interpretations. The
reader should provide an interpretation of the assay
based on the following criteria.
. Receptor positive (either ER or PgR). The Panel
recommends a cutoff of a minimum of 1% of tumor cells
positive for ER/PgR for a specimen to be considered
positive. There is no agreement about a range for
receptor equivocal, so this term should not be used.
. Receptor negative. Tumors exhibiting less than 1% of
tumor cells staining for ER or PgR of any intensity
should be considered negative based on data that such
patients do not receive meaningful benefit from
endocrine therapy. The sample should only be consid-
ered negative in the presence of appropriately stained
extrinsic and intrinsic controls. Any specimen lacking
intrinsic elements (normal breast epithelium) that is
negative on ER and/or PgR assay should be repeated
using another tumor block or another tumor specimen
and reported as uninterpretable rather than as negative.
. Receptor uninterpretable. The Panel agreed that there
are no absolute assay exclusions. Nevertheless, a result
should be considered uninterpretable if a sample did
not conform to preanalytic specifications of the guide-
line, was processed using procedures that did not
conform to guideline specifications or the laboratory’s
standard operating procedure, or the assay used to
analyze the specimen was not validated and controlled
as specified in the guideline. Examples of circumstances
that may lead to uninterpretable results include testing
of needle biopsies or cytology samples fixed in alcohol,
use of fixatives other than 10% neutral buffered
formalin ([NBF] unless that fixative has been validated
by the laboratory before offering the assay), biopsies
fixed for intervals shorter than 6 hours or longer than
72 hours, samples where fixation was delayed for more
than 1 hour, samples with prior decalcification using
strong acids, and samples with inappropriate staining
of internal assay controls (including intrinsic normal
epithelial elements) or extrinsic assay controls. These
conditions are not absolute because they depend on
which conditions have been validated by the laboratory
and which are subject to the judgment of the circum-
stances by the pathologist. The reason for an unin-
terpretable result should be specified (eg, fixation for
, 6 hours), and an alternative potential sample for
retesting should be suggested, if appropriate.
Two optional report elements are recommended by the
Panel, but not required.
1. A cautionary statement may be added to negative
ER and PgR interpretations when the histopathology of
the tumor is almost always associated with ER-positive
and PgR-positive results. These include tubular, lobular,
and mucinous histologic types or tumors with a Notting-
ham score of 1. The cautionary statement should indicate
that although the patient’s tumor tested as ER negative,
tumors with the same histologic type or Nottingham
score almost always test positive.
2. Using the percentage and intensity measurements
provided, the pathologist may also provide a composite
score such as the H score, Allred score, or quick score
(Table 3). Because each of these is somewhat differently
calculated and may lead to confusion across institutions,
scoring is not required.
Appropriate populations to be tested.—The Panel devel-
oped consensus that ER and PgR status should be
determined on all newly diagnosed invasive breast
cancers. For patients with multiple synchronous tumors,
testing should be performed on at least one of the tumors,
preferably the largest. The Panel acknowledges that all
newly diagnosed DCISs are also commonly being tested
for ER and PgR. This practice is based on the results of a
retrospective subset analysis of the National Surgical
Adjuvant Breast and Bowel Project (NSABP) B-24 clinical
trial comparing tamoxifen versus placebo after lumpecto-
my and radiation, which has thus far been reported only
in abstract form. There was a significant 40% to 50%
reduction in subsequent breast cancer (ipsilateral and
contralateral) restricted to patients with ER-positive DCIS
at 10 years of follow-up, and a full manuscript has recently
been submitted for peer review (personal communication
from NSABP, September 2009). Because the results are
scientifically reasonable and consistent with previous
studies of invasive/metastatic breast cancer, the Panel
sees value in assessing ER in patients with DCIS.
However, because there are unlikely to be any validation
studies, the Panel leaves it up to patients and their
physicians to decide on testing, rather than making a
formal recommendation. Breast recurrences should also
always be tested to ensure that prior negative results of
ER and/or PgR were not falsely negative and to evaluate
the specimen for biologic changes since the previous
testing.
What Strategies Can Ensure Optimal Performance,
Interpretation, and Reporting of Established Assays?
Summary and recommendations.—The Panel considered
those strategies that would ensure optimal performance of
ER/PgR testing, interpretation, and reporting and was
heavily influenced by the previous experience with the
implementation of the elements included in the ASCO/
CAP HER2 testing guideline. This guideline included
measures to improve standardization of preanalytical
variables, type of fixative and duration of tissue fixation,
antibodies and controls, and assay interpretation.
What Are the Preanalytic, Analytic, and Postanalytic
Variables That Must Be Controlled to Ensure That the
Assays Reflect the Tumor ER and PgR Status?
Preanalytic standardization: tissue handling.—The warm
and cold ischemic times are widely accepted as important
variables in the analysis of labile macromolecules such as
proteins, RNA, and DNA from clinical tissue samples.
Warm ischemia time is the time from the interruption of
the blood supply to the tumor by the surgeon to the
excision of the tissue specimen; cold ischemia time is the
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time from excision to the initiation of tissue fixation.
Numerous studies have documented the progressive loss
of activity of these labile molecules after the surgical
interruption of blood flow, leading to tissue ischemia,
acidosis, and enzymatic degradation.28–30 The contribution
to this macromolecular degradation by the warm ischemic
interval is currently under study. The standardization of
the time between tissue removal and the initiation of
fixation is an important step to help ensure that
differences in levels of protein expression for clinically
relevant targets such as ER are biologically meaningful
and are not an artifact related to the manner in which the
tissue was handled.
The breast resection specimen should be fixed as
quickly as possible in an adequate volume of fixative
(optimally 10-fold greater than volume of the specimen).
The time of tissue collection (defined as the time that the
tissue is handed from the surgical field) and the time the
tissue is placed in fixative both must be recorded on the
tissue specimen requisition to document the time to
fixation of the specimen. The pathologist should effec-
tively communicate this priority to all members of the
breast care management team so processes are put in place
to make sure these times are routinely recorded. It is the
responsibility of the surgeon and operating room staff or
the radiologist and his/her staff obtaining the specimen to
document the collection time, and it is the responsibility of
the pathologist and laboratory staff to document the
fixation start time. Every effort should be made to
transport breast excision specimens with a documented
or suspected cancer from the operating room to the
pathology laboratory as soon as they are available for an
immediate gross assessment. The time from tumor
removal to fixation should be kept to # 1 hour to comply
with these recommendations.
On receipt in the pathology laboratory, these specimens
should be oriented and carefully inked for surgical margin
assessment and then carefully sectioned at 5-mm intervals
and placed in 10% NBF. Gauze pads or paper towels
should be placed in between tissue slices to assist with the
penetration of formalin into all areas of the tissue sample if
the specimen will be further sectioned and placed into
tissue cassettes at a later time. If gross tumor is easily
identifiable, a small portion of tumor and fibrous normal
breast tissue can be included together in a cassette and
placed immediately into fixative at the time of the initial
gross evaluation. This will initiate good tissue fixation and
also ensure that normal breast elements are available as an
internal positive control that have been handled and fixed
in a manner that is identical to the tumor tissue. In
situations where excision specimens are obtained remote-
ly from the grossing laboratory, the pathologists should
work with personnel in the remote operating suites to
ensure that the sample is bisected through the tumor and
promptly placed in NBF before transport. The time to
insertion of tumor sample into fixative and the time of
removal of the tumor from the patient should be noted on
the specimen requisition by the remote personnel.
Although less optimal than immediate gross examination
of the fresh sample by the pathologist, this process is
preferable to storage of the sample in the refrigerator
unfixed or in fixative without sectioning.
Preanalytic standardization: type of fixative.—Only 10%
NBF should be used as the fixative for breast tissue
specimens. Higher or lower concentrations of NBF are not
acceptable. This recommendation is based on published
literature regarding the expected or characteristic immu-
noreactivity for ER in breast cancer, which has been
accrued over many years and has been clinically validated
with patient outcomes in numerous clinical trials.31 In
addition, FDA approval for assay kits analyzing ER and
HER2 explicitly states that formalin fixation should be
used and that the FDA approval for the kits is not
applicable if an alternative fixative is used. If the
laboratory uses a formalin alternative for fixation, the
assay must be validated against NBF fixation, and the
laboratory director assumes responsibility for the validity
of these assay results.
Preanalytic standardization: duration of tissue fixation.—
Breast tissue specimens must be fixed in 10% NBF for no
less than 6 hours and for not more than 72 hours before
processing.32,33 Further information about the need for
standardization of tissue fixation appears in the un-
abridged version of this guideline.
Analytic standardization: antibody selection for ER test-
ing.—The selection of antibodies for ER and PgR IHC
testing should be restricted to those reagents that have
well-established specificity and sensitivity and have been
clinically validated, demonstrating good correlation with
patient outcomes in published reports. Alternatively, the
results of laboratory-selected antibodies should be at least
90% concordant with those of the clinically validated
assay for the ER- and PgR-positive category and 95%
concordant with those for the ER- or PgR-negative
category that have been correlated with clinical outcomes
of endocrine treatment. The Panel determined that the
antibodies for ER that have met these criteria are clones
1D5, 6F11, SP1, and 1D5+ER.2.123, whereas the antibodies
for PgR include clones 1A6, 1294, and 312 (Table 3). There
is a single FDA 510(k)-cleared ER/PgR kit. Published
reports have demonstrated that each of these antibodies is
equivalent or superior to LBAs in terms of correlation
with outcome and/or benefit from endocrine therapy
(Tables 2 and 3). Antibodies sold as research use only or
investigational use only or developed by the testing
facility may not be used in ER and PgR testing. Use of
research use only, investigational use only, and laborato-
ry-developed antibodies in an assay is not compliant with
these guidelines.
Analytic standardization: control samples for ER and PgR
IHC assays.—Positive and negative controls should be
included with every ER and PgR IHC assay batch run.
Batch controls are used to monitor assay performance over
time and to detect a loss of sensitivity or assay analytic
drift. Acceptable batch controls include cell lines with
defined receptor content varying from high positive to
negative and including at least one intermediate level of
receptor content. Other acceptable external controls
include endometrial tissue with known receptor content.
On-slide external controls and internal normal epithelial
elements should be used to help ensure that all reagents
were dispensed onto the slide containing a test sample
and that the assay is performing properly. The internal
positive control must display a heterogeneous staining
pattern of the luminal cells, with a mixture of a variable
number of cells exhibiting weak, moderate, and intense
immunoreactivity. If the assay only highlights a few cells
among the normal breast epithelium with a homogeneous
staining pattern, then the risk of a false-negative assess-
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ment of the tumor ER and/or PgR is higher as a result of
an insufficient sensitivity of the reaction to detect the
tumor cells with a weak to moderate immunoreactivity.
The normal breast tissue also represents a useful built-in
negative control of the staining because the myoepithelial
cells and the stromal cells must invariably show a negative
result. In some specimens, there are no internal control
elements (normal breast epithelium); in this case, the
pathologist must exercise judgment as to whether the
assay can be interpreted based on the level of ER and/or
PgR positivity of the tumor cells, the histologic type of the
tumor, the fixation status of the tumor, and the status of
external controls.
To ensure that there has not been analytic drift because
of subtle differences in technique or dilution, controls with
intermediate reactivity or controls covering a spectrum of
expression should be scored and recorded daily (percent
positive tumor cells and intensity of staining) using
laboratory standard scoring system or image analysis. It
is not appropriate to use a single strong positive control
tissue to evaluate assay performance.
If an external or internal control does not produce the
expected reaction, the result of patient testing must not be
reported. Instead, the assay should be repeated with the
standard reagents under the standard conditions until
acceptable ER and/or PgR reactivity of control material is
achieved. No patient material should be reported until
controls react appropriately.
If the particular histologic type of breast cancer is
unlikely to be ER negative (tubular, mucinous, or lobular
morphology or Nottingham score of 1), the tumor should
also be subjected to confirmatory testing, such as sending
the same specimen to a reference laboratory for retesting
or by repeating the assay on another block or on a separate
breast cancer specimen.
Postanalytic standardization: interpretation of IHC assays
for ER and PgR.—The interpretation of ER and PgR
assays should include an evaluation of both the percent-
age of positive tumor cell nuclei and the intensity of the
staining reaction. The level of expression of ERs in
different breast tumors demonstrates a broad dynamic
range that can vary by several hundred–fold. There is still
no consensus about what level of expression constitutes
the equivocal range for ER/PgR, and this terminology
should not be used in the report. Table 4 lists interpreta-
tion guidelines.
Postanalytic standardization: reporting of ER and PgR by
IHC.—The elements to be reported are listed in Tables 5
and 6. The staining of normal breast elements, if present
within the specimen, should also be reported as an
additional check on the IHC assay performance.
Postanalytic standardization: ER and PgR IHC assay internal
quality control and validation.—A comprehensive quality
control program for ER/PgR IHC analyses should include
all aspects of the total test including periodic trend
analysis to help ensure an appropriate and expected
number of ER-positive breast cancers in the patient
population served by the laboratory. Table 7 lists specific
suggestions; additional suggestions are provided in a
separate publication.3
What Is the Regulatory Framework That Allows for
Increased Scrutiny?
The Clinical Laboratory Improvement Act of 1998
(CLIA 88) provides stringent quality standards for highly
Table 4. IHC ER/PgR Testing Interpretation Criteria
Review controls (external standard and internal normal breast epithelium if present). If not as expected, the test should be repeated and not
interpreted.
Provide an interpretation of the assay as receptor positive, receptor negative, or receptor uninterpretable.
Positive interpretation requires at least 1% of tumor cells showing positive nuclear staining of any intensity.
Receptor negative is reported if , 1% of tumor cells show staining of any intensity.
Receptor uninterpretable is reported if the assay controls are not as expected or the preanalytic or analytic conditions do not conform to the
guideline and there is no tumor cell staining in the absence of normally stained intrinsic epithelial elements.
Report the percentage of cells with nuclear staining using either estimation or quantitation. Quantitation may be done either by image
analysis or manually.
Entire slide should be reviewed to assess the tumor-containing areas. Cytology samples with limited tumor cells and little tumor staining must
have at least 100 cells counted.
Report an average intensity of tumor cell nuclei recorded as strong, moderate, or weak.
A score may be provided if the scoring system is specified.
Quantitative image analysis is encouraged for samples with low percentages of nuclear staining or in cases with multiple observers in the
same institution. It is also a valuable way to quantify intensity and assure day-to-day consistency of control tissue reactivity.
If cytoplasmic staining occurs, repeat assay or perform on another sample.
Reject sample if normal ducts and lobules do not show obvious staining of some cells with variable intensity in the presence of totally
negative tumor cells.
Reject sample if there are obscuring artifacts such as decalcification of sample or staining only of necrotic debris.
In samples with DCIS only, the type of DCIS should be mentioned and the DCIS may be scored for ER/PgR; in patients with invasive disease
and DCIS, ER/PgR should be reported only for the invasive component. DCIS staining pattern may also be provided in a comment
The ER and PgR results should fit the clinical profile of the patient being evaluated: Consider the type of invasive cancer and the grade of the
cancer in interpretation; some cancer types like lobular, mucinous, and tubular carcinoma are almost always strongly ER positive and only
rarely ER negative.
Abbreviations: IHC, immunohistochemistry; ER, estrogen receptor; PgR, progesterone receptor; DCIS, ductal carcinoma in situ.
Table 5. Elements to Be Included in Accession Slip for
ER and PgR Assays
Patient identification information
Physician identification
Date of procedure
Clinical indication for biopsy
Specimen site and type of specimen
Collection time
Time sample placed in fixative
Type of fixative
Fixation duration
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor.
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complex tests, which include all predictive cancer factor
assays. This legislation also requires application of
external controls to assure compliance with CLIA stan-
dards. These external controls include required successful
performance on external proficiency surveys (or alterna-
tive external assessment of assay accuracy) and on-site
biennial inspection of laboratories performing highly
complex tests with defined criteria and actions required
when performance is deemed deficient. On-site inspec-
tions may be performed by the Centers for Medicare and
Medicaid Services or its agents or by various deemed
private accreditors, including CAP, The Joint Commis-
sion, and COLA (formerly known as Commission on
Office Laboratory Accreditation).
The FDA regulates medical devices as a result of the
1976 Medical Devices Amendments Act. ER and PgR
testing reagents and kits, which have potentially high
impact on patient mortality and morbidity, have been the
subject of several guidance documents and reports
referencing FDA opinion on the subject.34
After review of the legislation and applicable regula-
tions, the Panel agreed that the current regulatory
framework provided sufficient justification for the guide-
line recommendations without modification, just as it had
for the previously published ASCO/CAP HER2 guide-
line. Other countries such as Australia and New Zealand
have similar requirements.
What Are the Optimal External Quality Assurance
Methods to Ensure Ongoing Accuracy in ER/PgR Testing?
Summary and recommendations.—The guideline is based
on regulatory requirements of CLIA 88, published studies,
Table 6. Reporting Elements for ER and PgR IHC Assays
Patient identification information*
Physician identification*
Date of service*
Specimen site and type*
Specimen identification (case and block number)*
Fixative
Cold ischemia time (time between removal and fixation)
Duration of fixation
Staining method used
Primary antibody and vendor
Assay details and other reagents/vendors
References supporting validation of assay (note: most commonly, these will be published studies performed by others that the testing
laboratory is emulating)
Status of FDA approval
Controls (high protein expression, low-level protein expression, negative protein expression, internal elements or from normal breast tissue
included with sample)
Adequacy of sample for evaluation
Results*
Percentage of invasive tumor cells exhibiting nuclear staining3
Intensity of staining: strong, medium, or weak
Interpretation:
Positive (for ER or PgR receptor protein expression), negative (for ER or PgR protein expression), or uninterpretable
Internal and external controls (positive, negative, or not present)
Standard assay conditions met/not met (including cold ischemic time and fixation parameters)
Optional score and scoring system
Comment: Should explain reason for uninterpretable result and or any other unusual conditions, if applicable; may report on status of
any DCIS staining in the sample; should also provide correlation with histologic type of the tumor; may provide information about
laboratory accreditation status
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; IHC, immunohistochemistry; FDA, US Food and Drug Administration.
* Report should contain these elements as a minimum. Other information must be available in the laboratory for review and/or appear on the patient
accession slip.
3 There is no recommendation in this guideline concerning whether specimens containing only ductal carcinoma in situ should be tested for ER/PgR.
Table 7. CAP Laboratory Accreditation Elements Requiring Documentation
Validation of test method before reporting patient results
Use and following of standard operating procedures with appropriate elements and sign-offs
Qualifications, responsibilities, and training of personnel involved in testing
Proper labeling of samples and reagents
Proper storage and handling of samples and reagents
Equipment calibration, maintenance, QC, and remedial action; proficiency testing performance and corrective actions when 100% not
achieved
Internal QA plan for entire testing process, evidence that it is followed, and identified problems monitored and resolved effectively
Quality of tests for interpretation
Ongoing competency assessment of technologists and pathologists*
Report adequacy and quality, including required dates and times
Recordkeeping for entire test process and record retention
Accurate, timely submission of results
Abbreviations: CAP, College of American Pathologists; QC, quality control; QA, quality assurance.
* Competency assessment is monitored by periodic or continuous review of performance of those doing tests against peers. When failure is
documented, remediation is undertaken.
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previous CAP experience,1,2 experience of other groups,31
and the Panel’s consensus.
Currently there are no regulatory requirements for
proficiency testing of ER or PgR assays in the United
States. CLIA regulations require alternative assessment
schemes for ER and PgR as substitutes for mandated
successful performance on external proficiency testing.
However, proficiency testing can be used to meet the
alternative assessment requirement if it is available. The
current guideline will make successful performance in
proficiency testing mandatory. There are mandatory
requirements for successful performance in proficiency
testing in Australia and New Zealand, which had been in
place since 2001.
The guidelines also require enhanced levels of scrutiny
at the time of laboratory inspection beyond those required
by CLIA. The Panel recommends that ER and PgR testing
be performed in a CAP-accredited laboratory or in a
laboratory that meets the additional accreditation require-
ments set out within this guideline.
External quality assurance (laboratory accreditation).—Be-
ginning in 2010, the CAP Laboratory Accreditation
Program will require that every CAP-accredited labora-
tory performing ER and/or PgR testing participate in a
proficiency testing program directed to these analytes.
Other Centers for Medicare and Medicaid Services–
approved certifying or accrediting organizations that wish
to evaluate laboratory compliance with this guideline
must bring their accreditation programs in conformance
with this and other requirements.
The CAP Laboratory Accreditation Program will mon-
itor performance in the required proficiency testing.
Performance less than 90% (described in detail in the
following section) will be considered unsatisfactory and
will require internal or external response consistent with
accreditation program requirements. Responses must
include identification of the cause of the poor perfor-
mance, actions taken to correct the problem, and evidence
that the problem has been corrected. Competency of the
laboratory personnel performing the ER/PgR testing,
including the pathologists, is an important aspect of the
laboratory proficiency. Competency of testing personnel
and pathologists must be assured by the laboratory
director of each facility in a manner consistent with CLIA.
Competency assessments must be documented, and
documentation shall be evaluated at the time of laboratory
inspection accreditation. The checklist of requirements for
laboratories is presented in Table 7.
Proficiency testing requirements.—All laboratories report-
ing ER and/or PgR results must participate in a guideline-
concordant proficiency testing program specific for each
assay and method used. To be concordant with this
guideline, proficiency testing programs must distribute
specimens at least twice per year including a sufficient
number of challenges (cases) to ensure adequate assess-
ment of laboratory performance. For programs with $ 10
challenges per event, satisfactory performance requires
correct identification of at least 90% of the graded
challenges in each testing event. Laboratories with less
than 90% correct responses on graded challenges in a
given proficiency testing event are at risk for the next
event. Laboratories that have unsatisfactory performance
will be required to respond according to accreditation
program requirements up to and including suspension of
ER and/or PgR testing for the applicable method until
performance issues are corrected. In some Canadian
provinces and within the United Kingdom, the method
of proficiency testing is different. In Canada, laboratories
may participate in proficiency testing that uses sections of
tissue microarrays offered by the Canadian Immunohis-
tochemistry Quality Control (an academic program
associated with the Canadian Association of Pathologists)
or tumor samples or sections of cell blocks with
characterized cell lines. Many Canadian laboratories also
participate in CAP proficiency testing programs or
European programs. The results may or may not be used
for laboratory accreditation depending on the province.
Laboratories receive unstained materials and must return
those materials to a central laboratory for review and
comment. The Australasian program developed by the
Royal College of Pathologists of Australasia Quality
Assurance Program consists of two components. Labora-
tories are sent unstained sections from tissue microarray
blocks and are required to stain these and return them for
central review and scoring. In addition, laboratories are
required to submit de-identified data on the ER/PgR and
HER2 status of reported breast cancers for evaluation of
acceptable performance. Enrollment and participation in
these programs are mandatory.
How Can These Efforts Be Implemented and the
Effects Measured?
Plans to ensure compliance with guideline.—ASCO and
CAP will provide educational opportunities (print, online,
and society meetings) to educate health care professionals,
patients, third-party payers, and regulatory agencies. In
addition, CAP is producing a certificate program for
pathologists that will assess their competency in following
both the hormone receptor and the HER2 guideline
recommendations. CAP will urge its members and
participants in accreditation and proficiency testing
programs to optionally append a statement to individual
results or laboratory informational or promotional mate-
rials indicating that the laboratory’s ER/PgR assays have
been validated and performed in accordance with ASCO/
CAP ER testing guidelines, provided that all of the
guideline conditions are met.
ASCO and CAP will work to coordinate these recom-
mendations with those of other organizations, such as the
National Comprehensive Cancer Network, the Commis-
sion of Cancer of the American College of Surgeons, the
American Joint Committee on Cancer, and patient
advocacy organizations.
We are confident that these guidelines and measures
developed for testing of ER, PgR, and HER2 will improve
performance of laboratories using these and future
predictive testing methods. CAP will actively review
results of proficiency testing and laboratory accreditation
activities and periodically publish performance results.
CAP will also work to include quality monitoring
activities of ER and PgR testing in its programs designed
for ongoing quality assessment, similar to its Q-tracks and
Q-probes. In Australasia, participation in the programs is
mandatory and linked to laboratory accreditation. In
Australia and New Zealand, the laboratory accreditation
is linked to funding of testing for laboratories ensuring
compliance.
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APPENDIX
Definitions
Analyte-specific reagent.—Antibodies, both polyclonal
and monoclonal, specific receptor proteins, ligands,
nucleic acid sequences, and similar reagents, which,
through specific binding or chemical reaction with
substances in a specimen, are intended for use in a
diagnostic application for identification and quantifica-
tion of an individual chemical substance or ligand in
biologic specimens [21CFR864.4020(a)].
Research use only (RUO).—Products that are in the
laboratory research phase of development (ie, either basic
research or the initial search for potential clinical utility)
and not represented as an effective in vitro diagnostic
product (21CFR809.10).
Investigational use only (IUO).—A product being shipped
or delivered for product testing before full commercial
marketing (for example, for use on specimens derived
from humans to compare the usefulness of the product
with other products or procedures that are in current use
or recognized as useful) (21CFR809.10).
Clinical laboratory.—A facility for the biologic, microbi-
ologic, serologic, chemical, immunohematologic, hema-
tologic, biophysical, cytologic, pathologic, or other
examination of materials derived from the human body
for the purpose of providing information for the
diagnosis, prevention, or treatment of any disease or
impairment of, or the assessment of the health of, human
beings. These examinations also include procedures to
determine, measure, or otherwise describe the presence
or absence of various substances or organisms in the
body. Facilities only collecting or preparing specimens
(or both) or only serving as a mailing service and not
performing testing are not considered laboratories
(42CFR493.2).
US Food and Drug Administration (FDA)–cleared test.—A
test that has been cleared by the FDA after analysis of data
showing substantial performance equivalence to other
tests being marketed for the same purpose. Such tests
typically follow the 510(k) approval route (21CFR807).
FDA-approved test.—A test that is classified as a class III
medical device and that has been approved by the FDA
through the premarket approval process (21CFR814.3).
Laboratory modified test.—An FDA-cleared or FDA-
approved test that is modified by a clinical laboratory,
but not to a degree that changes the stated purpose of the
test, approved test population, specimen type, specimen
handling, or claims related to interpretation of results.
Laboratory developed test (LDT).—A test developed
within a clinical laboratory that has both of the following
characteristics: is performed by the clinical laboratory in
which the test was developed and is neither FDA cleared
nor FDA approved.
Note: All laboratory modified tests are, by definition,
LDTs. An LDT may or may not use analyte-specific
reagent, RUO, or IUOs; the type of reagents and devices
used does not affect whether a test is classified as an LDT.
A laboratory is considered to have developed a test if the
test procedure or implementation of the test was created
by the laboratory performing the testing, irrespective of
whether fundamental research underlying the test was
developed elsewhere or reagents, equipment, or technol-
ogy integral to the test was purchased, adopted, or
licensed from another entity.
Validation of a test.—Confirmation through a defined
process that a test performs as intended or claimed.
Note: There is no universally acceptable procedure for
validating tests. The process for validating tests must take
into account the purpose for which a test is intended to be
used, claims made about the test, and the risks that may
prevent the test from serving its intended purpose or
meeting performance claims. Even FDA-approved and
FDA-cleared tests require limited revalidation in clinical
laboratories (a process often referred to as verification) to
establish that local implementation of the test can
reproduce a manufacturer’s validated claims. Tests that
use reagents or equipment that have not been validated
(such as RUOs or IUOs) typically pose increased risks that
require more extensive validation, as do tests used in more
loosely controlled settings. The determination of whether
a test has been adequately validated requires professional
judgment.
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Verification of a test.—An abbreviated process through
which a clinical laboratory establishes that its implemen-
tation of an FDA-approved and FDA-cleared test per-
forms in substantial conformance to a manufacturer’s
stated claims.
Analytic validity.—A test’s ability to accurately and
reliably measure the analyte (measurand) of interest.
The elements of analytic validity include the following, as
applicable.
. Accuracy. The closeness of agreement between the
average value obtained from a large series of measure-
ments and the true value of the analyte. Note:
Technically, the term accuracy refers to the measure
of the closeness of a single test result to the true value,
not the average of multiple results. The definition of
accuracy used here is what metrologists call trueness of
measurement and describes the popular (but technical-
ly incorrect) meaning of the word accuracy.
. Precision. The closeness of agreement between inde-
pendent results of measurements obtained under
stipulated conditions (the International Organization
of Standardization, 1993).
. Reportable range. For quantitative tests, the span of test
result values over which the laboratory can establish or
verify the accuracy of the instrument or test system
measurement response and over which results will be
reported. For semiquantitative, binary, and nominal/
categoric tests, the reportable range is all of the values
that can be reported by the test system (eg, 2+, 3+,
‘‘positive,’’ ‘‘negative,’’ Escherichia coli, Staphylococcus
aureus).
. Analytic sensitivity. For quantitative tests (including
semiquantitative tests), analytic sensitivity is the lowest
amount of analyte (measurand) in a sample that can be
detected with (stated) probability, although perhaps not
quantified as an exact value. For qualitative tests
(binary and nominal/categoric tests), analytic sensitiv-
ity is the proportion of instances in which the analyte/
measurand/identity is correctly detected, within a
stated CI.
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CLIA, Clinical Laboratory Improvement Act.
Table A2. Invited Guests to Open Session December
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Invited Guests Affiliation
Steven Shak, MD Genomic Health, Redwood
City, CA
Kenneth J. Bloom, MD Clarient, Aliso Viejo, CA
Patrick Roche, PhD Ventana Medical Systems,
Tucson, AZ
Allen M. Gown, MD PhenoPath Laboratories, Seattle,
WA
David L. Rimm, MD, PhD Yale University, New Haven, CT
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. Analytic specificity. Ability of a measurement proce-
dure to measure solely the measurand/analyte.
Note: Analytic validity is expressed in the context of a
defined set of test conditions (including standard operating
procedures and permissible specimen types) and an on-
going quality management regimen (including, as applica-
ble, ongoing quality control, periodic assay recalibration,
and external proficiency testing or alternative external
testing). If the test conditions or quality management
regimen changes, the analytic validity of a test may change.
Clinical validity.—A test’s ability to detect or predict a
disorder, prognostic risk, or other condition or to assist in
the management of patients. The elements of clinical
validity include the following, as applicable.
. Clinical sensitivity (clinical detection rate). The propor-
tion of individuals with a disorder, prognostic risk, or
condition who are detected by the test.
. Clinical specificity. The proportion of individuals
without a disorder, prognostic risk, or condition who
are excluded by the test.
. Reference limits. A value or range of values for an
analyte that assists in clinical decision making. Refer-
ence values are generally of two types—reference
intervals and clinical decision limits. A reference
interval is the range of test values expected for a
designated population of individuals. This may be the
central 95% interval of the distribution of values from
individuals who are presumed to be healthy (or
normal). For some analytes that reflect high-prevalence
conditions (such as cholesterol), significantly less than
95% of the population may be healthy. In this case, the
reference interval may be something other than the
central 95% of values. A clinical decision limit
represents the lower or upper limit of a test value at
which a specific clinical diagnosis is indicated or
specified course of action is recommended.
. Clinical utility. The clinical usefulness of the test. The
clinical utility is the net balance of risks and benefits
associated with using a test in a specific clinical setting.
Clinical utility does not take into consideration the
economic cost or economic benefit of testing and is to
be distinguished from cost-benefit and cost-effectiveness
analysis. Clinical utility focuses entirely on the probabil-
ities and magnitude of clinical benefit and clinical
harm that result from using a test in a particular clinical
context.
Note 1: The qualities listed in this appendix represent
the primary performance measurements that are used to
describe the clinical capabilities of a test. Other measures
of clinical validity may be applicable in particular
circumstances.
Note 2: Clinical validity is expressed in the context of a
defined test population and a defined testing procedure. If
the test population changes (eg, a change in the prevalence
of disease) or the testing procedure changes, the clinical
validity of a test may change.
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